PE20100365A1 - Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion - Google Patents

Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion

Info

Publication number
PE20100365A1
PE20100365A1 PE2009001195A PE2009001195A PE20100365A1 PE 20100365 A1 PE20100365 A1 PE 20100365A1 PE 2009001195 A PE2009001195 A PE 2009001195A PE 2009001195 A PE2009001195 A PE 2009001195A PE 20100365 A1 PE20100365 A1 PE 20100365A1
Authority
PE
Peru
Prior art keywords
antigens
cough
whole cell
per
type
Prior art date
Application number
PE2009001195A
Other languages
English (en)
Inventor
Rajesh Jain
Sukhjeet Singh
Lavit Jambu
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of PE20100365A1 publication Critical patent/PE20100365A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

SE REFIERE A UNA VACUNA DE COMBINACION LIQUIDA ESTABLE QUE CONTIENE: A) ANTIGENOS DE LA DIFTERIA (D) EN UNA CANTIDAD DE 1 A 40 Lf; B) ANTIGENOS DEL TETANOS (T) EN UNA CANTIDAD DE 1 A 25 Lf, DONDE LOS ANTIGENOS D Y T SON ADSORBIDOS EN FOSFATO DE ALUMINIO; C) ANTIGENOS DE LA TOS FERINA DE CELULAS ENTERAS (wP) EN UNA CANTIDAD DE 1 A 30 IOU POR 0.5 ML; D) ANTIGENOS DE LA VACUNA ANTIPOLIOMIELITICA INACTIVADA (IPV) TALES COMO CEPAS MAHONEY TIPO 1, MEF TIPO 2 Y SAUKETT TIPO 3, QUE SE ENCUENTRAN EN UNA CANTIDAD DE 1 A 50 DU, 1 A 15 DU Y 1 A 50 DU REPECTIVAMENTE, POR 0.5 ML; OPCIONALMENTE E) ANTIGENOS DE HAEMOPHILUS INFLUENZAE (Hib) EN UNA CANTIDAD DE 1 A 20 ug POR 0.5 ML, DONDE EL ANTIGENO Hib NO SE ADSORBE A NINGUN ADYUVANTE; F) ANTIGENOS DE HEPATITIS (Hep) EN UNA CANTIDAD DE 1 A 20 ug POR 0.5 ML, DONDE EL ANTIGENO Hep ES ADSORBIDO EN FOSFATO DE ALUMINIO; Y G) UN PRESERVANTE TAL COMO 2-FENOXIETANOL (2-POE). SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION. DICHA VACUNA ES UTIL PARA LA PROTECCION CONTRA ENFERMEDADES TALES COMO DIFTERIA, TETANOS, TOS FERINA DE CELULAS ENTERAS Y POLIOMIELITIS
PE2009001195A 2008-10-24 2009-10-22 Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion PE20100365A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2437DE2008 2008-10-24

Publications (1)

Publication Number Publication Date
PE20100365A1 true PE20100365A1 (es) 2010-05-21

Family

ID=42119002

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009001195A PE20100365A1 (es) 2008-10-24 2009-10-22 Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion

Country Status (14)

Country Link
US (1) US20110195087A1 (es)
EP (2) EP2529750A1 (es)
JP (1) JP2012506420A (es)
CN (1) CN102196817B (es)
AP (1) AP2011005700A0 (es)
AR (1) AR073957A1 (es)
BR (1) BRPI0920629A2 (es)
CA (1) CA2741393A1 (es)
CL (1) CL2011000913A1 (es)
CO (1) CO6430435A2 (es)
MA (1) MA32821B1 (es)
PE (1) PE20100365A1 (es)
RU (2) RU2504398C2 (es)
WO (1) WO2010046934A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102633898B (zh) * 2012-04-23 2013-11-27 成都欧林生物科技股份有限公司 一种Hib多糖与蛋白结合工艺的优化方法
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
CN106075428A (zh) * 2015-07-01 2016-11-09 北京科兴中维生物技术有限公司 一种免疫原性组合物及其制备方法
BR112018005291A2 (pt) * 2015-09-16 2018-10-09 Lg Chemical Ltd composição para vacina combinada para dosagem múltipla
SG11201900365WA (en) * 2016-08-26 2019-02-27 Serum Institute Of India Pvt Ltd Multivalent vaccine composition
MX2020000441A (es) * 2017-07-18 2020-08-17 Serum Inst Of India Pvt Ltd Una composicion inmunogenica que tiene estabilidad mejorada, inmunogeneicidad potenciada y reactogenicidad reducida y proceso para la preparacion de la misma.
JOP20190242A1 (ar) 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
WO2020165920A1 (en) * 2019-02-12 2020-08-20 Biological E Limited Multivalent vaccine composition
WO2021176409A1 (en) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Preservative combination for vaccine composition

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3097140A (en) 1958-10-31 1963-07-09 Merck & Co Inc Preparing a mixed polio, pertussis, tetanus, and diphtheria vaccine with benzethonium chloride
US3097142A (en) 1960-03-30 1963-07-09 Merck & Co Inc Benzyl alcohol stabilized polio vaccines and production thereof
SK280702B6 (sk) * 1992-05-23 2000-06-12 Smithkline Beecham Biologicals S. A. Kombinovaný očkovací prostriedok obsahujúci povrch
US6488934B1 (en) * 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
FR2734484B1 (fr) * 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
ATE339965T1 (de) 1996-07-02 2006-10-15 Aventis Pasteur Vielwertige dtp-polio-impfstoffe
HU227893B1 (en) * 2000-06-29 2012-05-29 Glaxosmithkline Biolog Sa Vaccine compositions
KR100385711B1 (ko) 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
GB0223355D0 (en) 2002-10-08 2002-11-13 Chiron Spa Vaccine
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
KR20030069918A (ko) 2003-06-25 2003-08-27 주식회사 삼정산업 간편 조립식 파렛트 판재, 간편 조립식 파렛트 중간지지구및 간편 조립식 파렛트와 그의 제작방법
GB0405787D0 (en) 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
BRPI0419023A (pt) * 2004-08-27 2007-12-11 Panacea Biotec Ltd vacina contra poliomielite inativada e derivada do genero sabin de vìrus da polio
EP2066344B2 (en) 2006-09-07 2016-06-29 GlaxoSmithKline Biologicals S.A. Inactivated Poliovirus combination vaccine

Also Published As

Publication number Publication date
RU2011120309A (ru) 2012-11-27
CN102196817A (zh) 2011-09-21
RU2504398C2 (ru) 2014-01-20
AP2011005700A0 (en) 2011-06-30
EP2361094A1 (en) 2011-08-31
BRPI0920629A2 (pt) 2016-01-12
MA32821B1 (fr) 2011-11-01
CL2011000913A1 (es) 2012-01-20
RU2613295C2 (ru) 2017-03-15
AR073957A1 (es) 2010-12-15
CA2741393A1 (en) 2010-04-29
EP2361094A4 (en) 2012-12-05
EP2529750A1 (en) 2012-12-05
WO2010046934A1 (en) 2010-04-29
CN102196817B (zh) 2016-04-06
RU2011135761A (ru) 2013-03-10
US20110195087A1 (en) 2011-08-11
CO6430435A2 (es) 2012-04-30
JP2012506420A (ja) 2012-03-15

Similar Documents

Publication Publication Date Title
PE20100365A1 (es) Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
PE20100366A1 (es) Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
MX346245B (es) Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria.
IN2012DN00650A (es)
NZ592977A (en) IgE CH3 PEPTIDE VACCINE
MY161965A (en) New influenza virus immunizing epitope
TN2009000557A1 (en) Influenza virus-like particles (vlps) comprising hemagglutinin produced within a plant
WO2009076778A8 (en) Recombinant influenza virus-like particles (vlps) produced in transgenic plants expressing hemagglutinin
UA112768C2 (uk) Європейський штам prrsv
WO2010019262A3 (en) Polyvalent vaccine
JP2013517773A5 (es)
MX2018010291A (es) Vacunas novedosas contra el virus de zika.
WO2012093406A3 (en) A combination heptavalent vaccine
NZ603863A (en) Concentration and lyophilization of influenza vaccine antigens
MX2015004171A (es) Conjugados de sacaridos no lineales.
NZ608143A (en) Recombinant modified vaccinia virus ankara (mva) influenza vaccine
MX349294B (es) Formulaciones virales liofilizadas.
CL2012003219A1 (es) Parapoxvirus recombinante que comprende un parapoxvirus y adn heterólogo derivado de un virus de la rabia; procedimiento de preparación de dicho parapoxvirus; composicion inmunogénica; uso de la composicion para inducir respuesta inmunitaria contra el virus de la rabia en un animal.
WO2008097267A3 (en) Vaccines against vesicular stomatitis
PE20141515A1 (es) Procedimiento de formulacion de una vacuna que contiene al menos dos antigenos susceptibles de adsorberse en oxihidroxido de aluminio
JP2016502995A5 (es)
WO2017116177A3 (ko) 약독화된 돼지열병 바이러스 생마커백신주 및 이를 이용한 경구투여용 백신 조성물
MX2012002702A (es) Vacuna de herpesvirus bovino.
AR067471A1 (es) Un componente de vacuna anti- pertussis y procedimiento simplificado para obtener pertactina ( prn ) de bordetella pertussis

Legal Events

Date Code Title Description
FA Abandonment or withdrawal